[BidClub_]

SHOW DIRECTORY

All-In

Industry veterans Chamath Palihapitiya, Jason Calacanis, David Sacks, and David Friedberg cover economics, technology, politics, society, and poker.

SOURCE DESCRIPTION · RSS

217 EPISODESENTRACKED SHOW
SUBSCRIBE[Feed_]
25 episodes2 active
Language
All-InEN · 85 min

Jensen OUT as Nvidia CEO: "Spy" Scandal, Export Restrictions, Market Impact

Chamath PalihapitiyaJason CalacanisDavid SacksDavid Friedberg

Jensen Huang’s reported departure puts Nvidia’s annual chip-advancement pace and America’s AI lead at risk, even as rivals still face the same manufacturing, networking and software challenges.The larger exposure may be the “bank of NVIDIA”: a successor could slow investment in startups and infrastructure, reducing the capital velocity that supports the AI ecosystem.Whether Huawei gains ground depends on how long Nvidia’s innovation cycle falters, while Anthropic’s proposed IPO pricing faces a November 20 market test tied partly to Nvidia developments.

All-InEN · 93 min

Midterm Blood Bath, $4T AI Sell Off, Data Center Freeze, What’s Next for Trump

Chamath PalihapitiyaJason CalacanisDavid SacksDavid Friedberg

Hosts frame the midterm defeat as an affordability revolt; Chamath makes economic fairness the 2028 test, while Sacks says ending the Iran war could bring Brent from as high as $117 toward $70.Permitting uncertainty may preserve meaningful 2027 data-center construction but shrink the 2028 pipeline; scarce compute could favor hyperscalers over model companies and neoclouds, with SpaceX–Anthropic’s mutual 90-day termination right a potential repricing trigger.

All-InEN · 25 min

Martin Shkreli: Big Pharma's Blind Spot, Betting Against Quantum & What Prison Taught Him

Martin Shkreli

Shkreli limits quantum’s edge to factoring and elliptic-curve logarithms; current machines lack quantum RAM.He calls industry spending speculative and expects analog optical computing to challenge Nvidia’s H100, B100, and B200 within 20 years.His pharmaceutical thesis favors mispriced discarded molecules; he calls AI drug discovery within five years “nonsense” and expects no AI-related drug in the next 10 years.

All-InEN · 18 min

Brad Gerstner: No AI Bubble, Semis Eat the Nasdaq & AI's Take Off Problem

Brad Gerstner

Gerstner argues the rally is earnings-driven, even as semiconductor concentration accounts for 70% of Nasdaq’s return.The AI buildout still depends on lab revenue scaling, while rates, power constraints, regulation and a delayed Anthropic IPO remain key risks.

All-InEN · 47 min

Jensen Huang: The Doomer Hoax, Superintelligence is Here, and The Future of AI (ft. President Trump)

Jensen HuangPresident Trump

Jensen Huang cites failed forecasts on radiology, AI-generated code and entry-level jobs to challenge doomsday narratives, while arguing that AI incidents so far call for root-cause engineering and independent evaluation rather than sweeping regulation.With 80% of AI-native companies receiving $400 billion in recent venture funding using open models, NVIDIA is building infrastructure bottlenecks as Jensen predicts China will reach advanced lithography by 2030, leaving commercialization, lab controls and data-center execution to monitor.

All-InEN · 97 min

Nvidia's Historic Quarter, SaaS Comeback, Bessent vs Druck, America's Debt Crisis, Cancer Vaccine

Chamath PalihapitiyaJason CalacanisDavid SacksDavid Friedberg

Nvidia’s $96.2B revenue and $60B net profit came with 70% growth guidance versus the Street’s 45%, despite supply constraints.Salesforce’s 20%+ rally on $5.90 adjusted EPS and a $46B guide suggests agents may reinforce horizontal systems of record, while vertical SaaS remains contested.Debt also bears watching: $10T must be refinanced within 12 months at a 5.2% 30-year rate.

All-InEN · 100 min

Anthropic's $2T IPO, Zuck's AI Manifesto, Nvidia's $500B AI Bet, Grok's Comeback

Gavin Baker

Anthropic’s reported $2T IPO figure may be banker theater rather than a clearing price, while Gavin Baker and Sacks estimate 2027 exit ARR at roughly $400–500B, constrained by physical supply.NVIDIA’s $500B financing effort could make GPU compute an asset class and support a capital-light cloud business, while Anthropic’s S-1 will test demand and dark-GPU risk.

All-InEN · 97 min

Chip Stocks Crash, $20B Fund Margin Called, Frontier Labs: SLOW DOWN AI, Mamdani's Grocery Stores

Chamath PalihapitiyaJason CalacanisDavid SacksDavid Friedberg

A roughly 3.5-times-levered public book was margin-called as semiconductor stocks fell more than 20%, showing leverage can break the trade before fundamentals do.The correction pits momentum against AI CapEx returns as 5.2% Treasury yields raise the hurdle, while model commoditization and frontier-lab safety incidents remain key risks to monitor.

All-InEN · 50 min

Former Intel CEO on What Went Wrong, What's Next + Lovable CEO on the Real Promise of Vibe Coding

Jason CalacanisPat GelsingerAnton Osika

Pat Gelsinger attributes Intel’s decline to replacing technical leadership with spreadsheet-driven capital allocation, while Apple, Nvidia and TSMC compounded patient capability-building into durable platforms.The semiconductor recovery remains exposed to Taiwan’s energy dependence, even as AI’s long runway is constrained by electricity; Lovable meanwhile reports production-scale adoption, with defensibility shifting toward orchestration, security, operational data and user feedback.

All-InEN · 102 min

Socialists Sweep NYC, China Catches Up in Coding, AI Memory Crunch, Micron's Blowout Quarter

Gavin BakerTravis Kalanick

Mamdani-backed challengers swept three safe Democratic New York districts despite Polymarket assigning only a 26% chance, demonstrating the DSA’s organizational leverage.The panel linked socialism’s momentum to housing, debt, inflation, and downward mobility, while GLM 5.2 brought a 744-billion-parameter, MIT-licensed model near the coding frontier at 85% lower cost than GPT 5.5.Open weights may shift value from frontier labs toward chips, memory, hosting, and routing, as Micron’s sold-out HBM supply makes DRAM and power the immediate constraints.